Evidence map›Paper›PMID 32141495›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa.

Marian Loveday, Jennifer Hughes, Babu Sunkari, Iqbal Master, Sindisiwe Hlangu, Tarylee Reddy, Sunitha Chotoo, Nathan Green, James A Seddon

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Observational
  6. Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Observational
  7. Review
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Marian LovedayHealth Systems Research Unit, South African Medical Research Council, KwaZulu-Natal, South Africa.
Jennifer HughesDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, South Africa.
Babu SunkariMDR-TB unit, King Dinuzulu Hospital, Durban, South Africa.
Iqbal MasterMDR-TB unit, King Dinuzulu Hospital, Durban, South Africa.
Sindisiwe HlanguHealth Systems Research Unit, South African Medical Research Council, KwaZulu-Natal, South Africa.
Tarylee ReddyDepartment of Biostatistics, South African Medical Research Council, KwaZulu-Natal, South Africa.
Sunitha ChotooMDR-TB unit, King Dinuzulu Hospital, Durban, South Africa.
Nathan GreenMDR-TB unit, King Dinuzulu Hospital, Durban, South Africa.
James A SeddonDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, South Africa.
South African Medical Research Council · ZAImperial College London · GBStellenbosch University · ZAUniversity of KwaZulu-Natal · ZA

Funding

Medical Research Council MR/R007942/1
6 · The paper itself

Abstract

backgroundData on safety and efficacy of second-line tuberculosis drugs in pregnant women and their infants are severely limited due to exclusion from clinical trials and expanded access programs.

methodsPregnant women starting treatment for multidrug/rifampicin-resistant (MDR/RR)-tuberculosis at King Dinuzulu Hospital in KwaZulu-Natal, South Africa, from 1 January 2013 to 31 December 2017, were included. We conducted a record review to describe maternal treatment and pregnancy outcomes, and a clinical assessment to describe infant outcomes.

resultsOf 108 pregnant women treated for MDR/RR-tuberculosis, 88 (81%) were living with human immunodeficiency virus.. Favorable MDR/RR-tuberculosis treatment outcomes were reported in 72 (67%) women. Ninety-nine (91%) of the 109 babies were born alive, but overall, 52 (48%) women had unfavorable pregnancy outcomes. Fifty-eight (54%) women received bedaquiline, and 49 (45%) babies were exposed to bedaquiline in utero. Low birth weight was reported in more babies exposed to bedaquiline compared to babies not exposed (45% vs 26%; P = .034). In multivariate analyses, bedaquiline and levofloxacin, drugs often used in combination, were both independently associated with increased risk of low birth weight. Of the 86 children evaluated at 12 months, 72 (84%) had favorable outcomes; 88% of babies exposed to bedaquiline were thriving and developing normally compared to 82% of the babies not exposed.

conclusionsMDR/RR-tuberculosis treatment outcomes among pregnant women were comparable to nonpregnant women. Although more babies exposed to bedaquiline were of low birth weight, over 80% had gained weight and were developing normally at 1 year.

Indexed as

RifampinTuberculosisAntitubercular AgentsChildFemaleHumansInfantPregnancyPregnant PeopleSouth AfricaAntitubercular AgentsRifampindrug-resistantoutcomepregnancytreatmenttuberculosis

Identifiers

PMID32141495
PMCPMC8028100
OpenAlexW3009508810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.